Welcome to our dedicated page for Astrana Health SEC filings (Ticker: ASTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Astrana Health, Inc. (NASDAQ: ASTH), a physician-centric, AI-powered and technology-enabled healthcare company focused on value-based care and population health management. Through these filings, investors can review how Astrana reports its financial condition, segment performance, acquisitions, and other material events.
Astrana’s periodic reports, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, describe the company’s three reportable segments—Care Partners, Care Delivery, and Care Enablement—and present detailed revenue and expense information. These filings also discuss topics such as medical liabilities, long-term debt, noncontrolling interests, and the structure of consolidated entities and variable interest entities.
Current reports on Form 8-K and amendments on Form 8-K/A document significant developments, including quarterly earnings announcements, updated investor presentations, and the completion and accounting treatment of acquisitions. For example, Astrana has filed 8-Ks and 8-K/As related to the closing of the Prospect Health acquisition, associated credit agreements, and the inclusion of audited financial statements and unaudited pro forma financial information for the acquired business.
Investors interested in transaction details, guidance updates, and capital structure changes can use these filings to understand how Astrana finances acquisitions, manages leverage, and integrates new entities into its operations. Regulation FD disclosures and furnished exhibits, such as earnings presentations and investor decks, offer additional context on the company’s strategy and performance.
Stock Titan’s tools surface Astrana Health’s latest SEC filings in near real time and apply AI-powered summaries to help explain the key points in lengthy documents. Users can quickly scan 10-K and 10-Q highlights, review 8-K event descriptions, and identify exhibits related to acquisitions, credit facilities, and pro forma financials. Form 4 insider transaction filings, when available, can also be accessed to see reported trading activity by company insiders.
By using this SEC filings page, readers gain a structured view of Astrana Health’s regulatory disclosures, from core financial statements to acquisition-related information and investor communications, supported by AI-generated insights that make complex filings easier to interpret.
Astrana Health insider sale and equity schedule
The company's COO and CFO, Basho Chandan, reported a disposition of 1,979 shares of common stock on
Mitchell W. Kitayama, a director of Astrana Health, Inc. (ASTH), reported multiple transactions on 09/15/2025. He exercised 8,000 stock options with an $18.20 exercise price, resulting in the acquisition of 8,000 common shares. The filing also shows the issuer repurchased a total of 13,214 shares (8,000 and 5,214 reported disposals at $30.23 each). After these transactions, Kitayama beneficially owned 15,846 shares, which includes 6,449 restricted shares that vest on the earlier of June 11, 2026 or the date of the issuer's 2026 annual meeting. The options that were exercised were fully vested and exercisable and convert into 8,000 common shares.
Astrana Health, Inc. reports it has completed the acquisition of all outstanding equity interests of Prospect Health Plan, Inc. and Alta Newport Hospital, LLC (d/b/a Foothill Regional Medical Center), and substantially all assets of certain direct and indirect subsidiaries of PHP Holdings, LLC, pursuant to an Asset and Equity Purchase Agreement dated November 8, 2024. The filing amends a prior Current Report on Form 8-K to incorporate Exhibits 99.1, 99.2 and 99.3 by reference.
The filing states that Unaudited Pro Forma Financial Statements are presented to give effect to the Transaction and related transactions. The document does not state purchase price, consideration, pro forma amounts, or other financial detail in the text provided here.
Basho Chandan, Astrana Health (ASTH) COO and CFO, reported a Form 4 disclosing a transaction on 09/05/2025 in which 1,694 shares of common stock were surrendered to cover tax withholding for vested restricted stock units at an effective price of $29.70 per share. After the surrender, the filing shows beneficial ownership of 176,946 shares.
The filing also details unvested restricted stock and restricted stock unit schedules: 7,214 shares vesting 4/14/2026; 30,404 shares vesting in two equal annual installments on 5/16/2026 and 5/16/2027; 23,404 RSUs vesting in six semi-annual installments beginning 10/02/2025; and 23,364 RSUs vesting in seven semi-annual installments beginning 03/05/2026. The transaction is coded F and represents a tax-withholding surrender, a routine insider action.
Astrana Health insider filing: Chief Medical Officer Dinesh M. Kumar reported a transaction on 09/05/2025 surrendering 1,694 shares of common stock to cover tax withholding on restricted stock units that vested the same day. After the surrender, Mr. Kumar beneficially owns 217,893 shares. The filing details multiple outstanding restricted stock and restricted stock unit awards that remain subject to continued employment and, for some grants, performance conditions: 56,754 shares vesting in two equal annual installments beginning 01/23/2026; 13,464 shares vesting 01/01/2026; performance-based grants of 8,158 and 3,264 shares; 67,238 RSUs subject to performance goals; 23,364 RSUs vesting in seven equal semi-annual installments beginning 03/05/2026. The filing also notes 1,405 shares held from the Employee Stock Purchase Plan.
David Schmidt, a director of Astrana Health, Inc. (ASTH), reported option exercise and subsequent disposition on 09/02/2025. He exercised a stock option with an $18.20 exercise price to acquire 20,000 shares, and those 20,000 shares were subsequently disposed of (repurchased by the issuer) at $27.76. After these transactions, Schmidt beneficially owned 15,763 shares, which include 6,449 restricted shares that vest on the earlier of June 11, 2026 or the 2026 annual meeting. The reported derivative position shows the exercised options were fully vested and exercisable; following the transactions there are 0 derivative securities reported.
Director John Chiang of Astrana Health, Inc. (ASTH) reported insider transactions on 08/13/2025. The filing shows an acquisition of 20,000 common shares through exercise of stock options at an effective price of $18.20 per share, and a separate disposition of 12,284 common shares sold at $29.63 per share. Following the reported transactions, the filing lists beneficial ownership amounts of 43,132 and 30,848 shares (the latter includes 6,449 restricted shares that vest by June 11, 2026 or at the issuer's 2026 annual meeting).
The form notes the exercised options were fully vested and exercisable. The report is signed by an attorney-in-fact on the reporting person's behalf.
FAQ
What is the current stock price of Astrana Health (ASTH)?
What is the market cap of Astrana Health (ASTH)?
